A Plus for ABBVIE
U.S. patent officials on Thursday denied petitions by Amgen to review two formulation patents on AbbVie's Humira, a potential setback in Amgen efforts to market a biosimilar version of the world's top-selling prescription medicine.
In June, Amgen, the world's biggest biotechnology company, asked the U.S. Patent and Trademark Office for the review, arguing that the patents should not have been granted in the first place for Humira, a rheumatoid arthritis drug with annual sales approaching $14 billion.
In declining to review the patents, the agency said "we determine, based on the Petition and the accompanying evidence, that Amgen has not shown a reasonable likelihood of prevailing on any of its challenges."
